ID   PMGE_HUMAN              Reviewed;         259 AA.
AC   P07738; A4D1N9;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Bisphosphoglycerate mutase;
DE            Short=BPGM;
DE            EC=5.4.2.4 {ECO:0000269|PubMed:21045285};
DE   AltName: Full=2,3-bisphosphoglycerate mutase, erythrocyte;
DE   AltName: Full=2,3-bisphosphoglycerate synthase;
DE            EC=5.4.2.11 {ECO:0000269|PubMed:21045285};
DE   AltName: Full=2,3-diphosphoglycerate mutase;
DE            Short=DPGM;
DE   AltName: Full=BPG-dependent PGAM;
GN   Name=BPGM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PARTIAL PROTEIN SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY,
RP   IDENTIFICATION OF VARIANT BPGMD CYS-90, AND CHARACTERIZATION OF
RP   VARIANT BPGMD CYS-90.
RX   PubMed=2542247;
RA   Rosa R., Blouquit Y., Calvin M.C., Prome D., Prome J.C., Rosa J.;
RT   "Isolation, characterization, and structure of a mutant 89 ArgTO:
RT   bisphosphoglycerate mutase. Implication of the active site in the
RT   mutation.";
RL   J. Biol. Chem. 264:7837-7843(1989).
RN   [2]
RP   PRELIMINARY PROTEIN SEQUENCE OF 2-259, CLEAVAGE OF INITIATOR
RP   METHIONINE, AND TISSUE SPECIFICITY.
RX   PubMed=6313356;
RA   Haggarty N.W., Dunbar B., Fothergill L.A.;
RT   "The complete amino acid sequence of human erythrocyte
RT   diphosphoglycerate mutase.";
RL   EMBO J. 2:1213-1220(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=3023066;
RA   Joulin V., Peduzzi J., Romeo P.-H., Rosa R., Valentin C., Dubart A.,
RA   Lapeyre B., Blouquit Y., Garel M.-C., Goossens M., Rosa J.,
RA   Cohen-Solal M.;
RT   "Molecular cloning and sequencing of the human erythrocyte 2,3-
RT   bisphosphoglycerate mutase cDNA: revised amino acid sequence.";
RL   EMBO J. 5:2275-2283(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3036106;
RA   Cohen-Solal M., Joulin V., Romeo P.-H., Rosa R., Valentin C.,
RA   Garel M.-C., Rosa J.;
RT   "Molecular cloning of the human 2,3-bisphosphoglycerate mutase cDNA
RT   and revised amino acid sequence.";
RL   Biomed. Biochim. Acta 46:S126-S130(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2844822;
RA   Joulin V., Garel M.-C., le Boulch P., Valentin C., Rosa R., Rosa J.,
RA   Cohen-Solal M.;
RT   "Isolation and characterization of the human 2,3-bisphosphoglycerate
RT   mutase gene.";
RL   J. Biol. Chem. 263:15785-15790(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-46; 144-168 AND 182-206, GLYCATION AT LYS-3;
RP   LYS-5; LYS-18; LYS-43; LYS-159 AND LYS-197, AND LACK OF GLYCATION AT
RP   LYS-29; LYS-46; LYS-143; LYS-181; LYS-246; LYS-247; LYS-253; LYS-258
RP   AND LYS-259.
RX   PubMed=9832630; DOI=10.1093/oxfordjournals.jbchem.a022243;
RA   Fujita T., Suzuki K., Tada T., Yoshihara Y., Hamaoka R., Uchida K.,
RA   Matuo Y., Sasaki T., Hanafusa T., Taniguchi N.;
RT   "Human erythrocyte bisphosphoglycerate mutase: inactivation by
RT   glycation in vivo and in vitro.";
RL   J. Biochem. 124:1237-1244(1998).
RN   [11]
RP   PROTEIN SEQUENCE OF 104-114.
RX   PubMed=8440681;
RA   Stafforini D.M., Rollins E.N., Prescott S.M., McIntyre T.M.;
RT   "The platelet-activating factor acetylhydrolase from human
RT   erythrocytes. Purification and properties.";
RL   J. Biol. Chem. 268:3857-3865(1993).
RN   [12]
RP   ENZYME REGULATION.
RX   PubMed=10477269; DOI=10.1042/bj3420581;
RA   Mulquiney P.J., Kuchel P.W.;
RT   "Model of 2,3-bisphosphoglycerate metabolism in the human erythrocyte
RT   based on detailed enzyme kinetic equations: equations and parameter
RT   refinement.";
RL   Biochem. J. 342:581-596(1999).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=16246416; DOI=10.1016/j.placenta.2005.08.010;
RA   Pritlove D.C., Gu M., Boyd C.A., Randeva H.S., Vatish M.;
RT   "Novel placental expression of 2,3-bisphosphoglycerate mutase.";
RL   Placenta 27:924-927(2006).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-122, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   3D-STRUCTURE MODELING.
RX   PubMed=1387804; DOI=10.1016/0300-9084(92)90149-9;
RA   Craescu C.T., Schaad O., Garel M.-C., Rosa R., Edelstein S.J.;
RT   "Structural modeling of the human erythrocyte bisphosphoglycerate
RT   mutase.";
RL   Biochimie 74:519-526(1992).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1-259, AND SUBUNIT.
RX   PubMed=15258155; DOI=10.1074/jbc.M405982200;
RA   Wang Y., Wei Z., Bian Q., Cheng Z., Wan M., Liu L., Gong W.;
RT   "Crystal structure of human bisphosphoglycerate mutase.";
RL   J. Biol. Chem. 279:39132-39138(2004).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-258 IN COMPLEXES WITH
RP   3-PHOSPHO-D-GLYCERATE AND 2,3-BISPHOSPHO-D-GLYCERATE, SUBUNIT, AND
RP   ACTIVE SITE.
RX   PubMed=17052986; DOI=10.1074/jbc.M606421200;
RA   Wang Y., Liu L., Wei Z., Cheng Z., Lin Y., Gong W.;
RT   "Seeing the process of histidine phosphorylation in human
RT   bisphosphoglycerate mutase.";
RL   J. Biol. Chem. 281:39642-39648(2006).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS), CATALYTIC ACTIVITY, AND ENZYME
RP   REGULATION.
RX   PubMed=21045285; DOI=10.1107/S1744309110035475;
RA   Patterson A., Price N.C., Nairn J.;
RT   "Unliganded structure of human bisphosphoglycerate mutase reveals
RT   side-chain movements induced by ligand binding.";
RL   Acta Crystallogr. F 66:1415-1420(2010).
RN   [21]
RP   VARIANT BPGMD CYS-90.
RX   PubMed=1421379;
RA   Lemarchandel V., Joulin V., Valentin C., Rosa R., Galacteros F.,
RA   Rosa J., Cohen-Solal M.;
RT   "Compound heterozygosity in a complete erythrocyte bisphosphoglycerate
RT   mutase deficiency.";
RL   Blood 80:2643-2649(1992).
RN   [22]
RP   VARIANT BPGMD GLN-62.
RX   PubMed=15054810; DOI=10.1002/ajh.20014;
RA   Hoyer J.D., Allen S.L., Beutler E., Kubik K., West C., Fairbanks V.F.;
RT   "Erythrocytosis due to bisphosphoglycerate mutase deficiency with
RT   concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.";
RL   Am. J. Hematol. 75:205-208(2004).
CC   -!- FUNCTION: Plays a major role in regulating hemoglobin oxygen
CC       affinity by controlling the levels of its allosteric effector 2,3-
CC       bisphosphoglycerate (2,3-BPG). Also exhibits mutase (EC 5.4.2.1)
CC       activity.
CC   -!- CATALYTIC ACTIVITY: 3-phospho-D-glyceroyl phosphate = 2,3-
CC       bisphospho-D-glycerate. {ECO:0000269|PubMed:21045285}.
CC   -!- CATALYTIC ACTIVITY: 2-phospho-D-glycerate = 3-phospho-D-glycerate.
CC       {ECO:0000269|PubMed:21045285}.
CC   -!- ENZYME REGULATION: At alkaline pH BPGM favors the synthase
CC       reaction; however, at lower pH the phosphatase reaction is
CC       dominant. Inhibited by citrate. {ECO:0000269|PubMed:10477269,
CC       ECO:0000269|PubMed:21045285}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15258155,
CC       ECO:0000269|PubMed:17052986}.
CC   -!- TISSUE SPECIFICITY: Expressed in red blood cells. Expressed in
CC       non-erythroid cells of the placenta; present in the
CC       syncytiotrophoblast layer of the placental villi at the feto-
CC       maternal interface (at protein level).
CC       {ECO:0000269|PubMed:16246416, ECO:0000269|PubMed:3023066,
CC       ECO:0000269|PubMed:6313356}.
CC   -!- PTM: Glycation of Lys-159 in diabetic patients inactivates the
CC       enzyme.
CC   -!- DISEASE: Bisphosphoglycerate mutase deficiency (BPGMD)
CC       [MIM:222800]: A disease characterized by hemolytic anemia,
CC       splenomegaly, cholelithiasis and cholecystitis.
CC       {ECO:0000269|PubMed:1421379, ECO:0000269|PubMed:15054810,
CC       ECO:0000269|PubMed:2542247}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphoglycerate mutase family. BPG-
CC       dependent PGAM subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04327; CAA27858.1; -; mRNA.
DR   EMBL; M23068; AAA51840.1; -; Genomic_DNA.
DR   EMBL; M23067; AAA51840.1; JOINED; Genomic_DNA.
DR   EMBL; AK315439; BAG37827.1; -; mRNA.
DR   EMBL; CH236950; EAL24067.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83821.1; -; Genomic_DNA.
DR   EMBL; BC017050; AAH17050.1; -; mRNA.
DR   CCDS; CCDS5833.1; -.
DR   PIR; A31999; PMHUBM.
DR   RefSeq; NP_001280014.1; NM_001293085.1.
DR   RefSeq; NP_001715.1; NM_001724.4.
DR   RefSeq; NP_954655.1; NM_199186.2.
DR   RefSeq; XP_011514829.1; XM_011516527.1.
DR   UniGene; Hs.198365; -.
DR   PDB; 1T8P; X-ray; 2.50 A; A/B=1-259.
DR   PDB; 2A9J; X-ray; 2.00 A; A/B=1-259.
DR   PDB; 2F90; X-ray; 2.00 A; A/B=1-259.
DR   PDB; 2H4X; X-ray; 1.85 A; A/B=1-259.
DR   PDB; 2H4Z; X-ray; 2.00 A; A/B=1-259.
DR   PDB; 2H52; X-ray; 2.00 A; A/B=1-259.
DR   PDB; 2HHJ; X-ray; 1.50 A; A/B=1-259.
DR   PDB; 3NFY; X-ray; 1.94 A; A/B=1-259.
DR   PDBsum; 1T8P; -.
DR   PDBsum; 2A9J; -.
DR   PDBsum; 2F90; -.
DR   PDBsum; 2H4X; -.
DR   PDBsum; 2H4Z; -.
DR   PDBsum; 2H52; -.
DR   PDBsum; 2HHJ; -.
DR   PDBsum; 3NFY; -.
DR   ProteinModelPortal; P07738; -.
DR   SMR; P07738; -.
DR   BioGrid; 107137; 21.
DR   IntAct; P07738; 8.
DR   STRING; 9606.ENSP00000342032; -.
DR   DEPOD; P07738; -.
DR   iPTMnet; P07738; -.
DR   PhosphoSitePlus; P07738; -.
DR   BioMuta; BPGM; -.
DR   DMDM; 130350; -.
DR   REPRODUCTION-2DPAGE; IPI00215979; -.
DR   EPD; P07738; -.
DR   MaxQB; P07738; -.
DR   PaxDb; P07738; -.
DR   PeptideAtlas; P07738; -.
DR   PRIDE; P07738; -.
DR   DNASU; 669; -.
DR   Ensembl; ENST00000344924; ENSP00000342032; ENSG00000172331.
DR   Ensembl; ENST00000393132; ENSP00000376840; ENSG00000172331.
DR   Ensembl; ENST00000418040; ENSP00000399838; ENSG00000172331.
DR   GeneID; 669; -.
DR   KEGG; hsa:669; -.
DR   UCSC; uc003vrv.4; human.
DR   CTD; 669; -.
DR   DisGeNET; 669; -.
DR   GeneCards; BPGM; -.
DR   HGNC; HGNC:1093; BPGM.
DR   HPA; HPA016493; -.
DR   HPA; HPA028735; -.
DR   MalaCards; BPGM; -.
DR   MIM; 222800; phenotype.
DR   MIM; 613896; gene.
DR   neXtProt; NX_P07738; -.
DR   OpenTargets; ENSG00000172331; -.
DR   Orphanet; 714; Hemolytic anemia due to diphosphoglycerate mutase deficiency.
DR   PharmGKB; PA25401; -.
DR   eggNOG; KOG0235; Eukaryota.
DR   eggNOG; COG0588; LUCA.
DR   GeneTree; ENSGT00390000016700; -.
DR   HOGENOM; HOG000221682; -.
DR   HOVERGEN; HBG027528; -.
DR   InParanoid; P07738; -.
DR   KO; K01837; -.
DR   OMA; KEAQNCG; -.
DR   OrthoDB; EOG091G0GIS; -.
DR   PhylomeDB; P07738; -.
DR   TreeFam; TF300007; -.
DR   BioCyc; MetaCyc:HS10491-MONOMER; -.
DR   BRENDA; 3.1.3.13; 2681.
DR   BRENDA; 5.4.2.4; 2681.
DR   Reactome; R-HSA-70326; Glucose metabolism.
DR   SABIO-RK; P07738; -.
DR   ChiTaRS; BPGM; human.
DR   EvolutionaryTrace; P07738; -.
DR   GenomeRNAi; 669; -.
DR   PRO; PR:P07738; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000172331; -.
DR   CleanEx; HS_BPGM; -.
DR   ExpressionAtlas; P07738; baseline and differential.
DR   Genevisible; P07738; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0046538; F:2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity; IBA:GO_Central.
DR   GO; GO:0004082; F:bisphosphoglycerate mutase activity; TAS:Reactome.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006094; P:gluconeogenesis; IBA:GO_Central.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IBA:GO_Central.
DR   GO; GO:0043456; P:regulation of pentose-phosphate shunt; IBA:GO_Central.
DR   GO; GO:0007585; P:respiratory gaseous exchange; TAS:ProtInc.
DR   CDD; cd07067; HP_PGM_like; 1.
DR   Gene3D; 3.40.50.1240; -; 1.
DR   HAMAP; MF_01039; PGAM_GpmA; 1.
DR   InterPro; IPR013078; His_Pase_superF_clade-1.
DR   InterPro; IPR029033; His_PPase_superfam.
DR   InterPro; IPR001345; PG/BPGM_mutase_AS.
DR   InterPro; IPR005952; Phosphogly_mut1.
DR   PANTHER; PTHR11931; PTHR11931; 1.
DR   Pfam; PF00300; His_Phos_1; 2.
DR   SMART; SM00855; PGAM; 1.
DR   SUPFAM; SSF53254; SSF53254; 1.
DR   TIGRFAMs; TIGR01258; pgm_1; 1.
DR   PROSITE; PS00175; PG_MUTASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycation; Glycolysis;
KW   Glycoprotein; Hereditary hemolytic anemia; Hydrolase; Isomerase;
KW   Phosphoprotein; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:6313356,
FT                                ECO:0000269|PubMed:9832630}.
FT   CHAIN         2    259       Bisphosphoglycerate mutase.
FT                                /FTId=PRO_0000179834.
FT   REGION       10     17       Substrate binding.
FT                                {ECO:0000269|PubMed:17052986}.
FT   REGION       23     24       Substrate binding.
FT                                {ECO:0000269|PubMed:17052986}.
FT   REGION       89     92       Substrate binding.
FT                                {ECO:0000269|PubMed:17052986}.
FT   REGION      116    117       Substrate binding.
FT                                {ECO:0000269|PubMed:17052986}.
FT   REGION      189    190       Substrate binding.
FT                                {ECO:0000269|PubMed:17052986}.
FT   ACT_SITE     11     11       Tele-phosphohistidine intermediate.
FT                                {ECO:0000269|PubMed:17052986}.
FT   ACT_SITE     89     89       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:17052986}.
FT   BINDING      62     62       Substrate. {ECO:0000269|PubMed:17052986}.
FT   BINDING     100    100       Substrate. {ECO:0000269|PubMed:17052986}.
FT   SITE         29     29       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE         46     46       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        143    143       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        181    181       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        188    188       Transition state stabilizer.
FT                                {ECO:0000269|PubMed:17052986}.
FT   SITE        246    246       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        247    247       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        253    253       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        258    258       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   SITE        259    259       Not glycated.
FT                                {ECO:0000269|PubMed:9832630}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     122    122       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD      3      3       N-linked (Glc) (glycation) lysine; in
FT                                vitro. {ECO:0000269|PubMed:9832630}.
FT   CARBOHYD      5      5       N-linked (Glc) (glycation) lysine; in
FT                                vitro. {ECO:0000269|PubMed:9832630}.
FT   CARBOHYD     18     18       N-linked (Glc) (glycation) lysine; in
FT                                vitro. {ECO:0000269|PubMed:9832630}.
FT   CARBOHYD     43     43       N-linked (Glc) (glycation) lysine; in
FT                                vitro. {ECO:0000269|PubMed:9832630}.
FT   CARBOHYD    159    159       N-linked (Glc) (glycation) lysine.
FT                                {ECO:0000269|PubMed:9832630}.
FT   CARBOHYD    197    197       N-linked (Glc) (glycation) lysine; in
FT                                vitro. {ECO:0000269|PubMed:9832630}.
FT   VARIANT      62     62       R -> Q (in BPGMD; dbSNP:rs751972865).
FT                                {ECO:0000269|PubMed:15054810}.
FT                                /FTId=VAR_065367.
FT   VARIANT      90     90       R -> C (in BPGMD; mutation identified at
FT                                protein level; marked decrease in
FT                                synthase and mutase activities; no effect
FT                                on phosphatase activity;
FT                                dbSNP:rs121964925).
FT                                {ECO:0000269|PubMed:1421379,
FT                                ECO:0000269|PubMed:2542247}.
FT                                /FTId=VAR_065368.
FT   STRAND        4     10       {ECO:0000244|PDB:2HHJ}.
FT   HELIX        15     18       {ECO:0000244|PDB:2HHJ}.
FT   HELIX        32     47       {ECO:0000244|PDB:2HHJ}.
FT   STRAND       53     57       {ECO:0000244|PDB:2HHJ}.
FT   HELIX        61     74       {ECO:0000244|PDB:2HHJ}.
FT   STRAND       81     83       {ECO:0000244|PDB:2HHJ}.
FT   HELIX        85     87       {ECO:0000244|PDB:2HHJ}.
FT   HELIX        93     95       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       100    107       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       109    117       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       133    137       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       140    142       {ECO:0000244|PDB:2HHJ}.
FT   STRAND      144    147       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       149    151       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       158    172       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       174    178       {ECO:0000244|PDB:2HHJ}.
FT   STRAND      183    187       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       189    200       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       206    209       {ECO:0000244|PDB:2HHJ}.
FT   STRAND      218    222       {ECO:0000244|PDB:2HHJ}.
FT   STRAND      228    230       {ECO:0000244|PDB:2HHJ}.
FT   HELIX       238    250       {ECO:0000244|PDB:2HHJ}.
SQ   SEQUENCE   259 AA;  30005 MW;  A2AF1D6F2985A3B5 CRC64;
     MSKYKLIMLR HGEGAWNKEN RFCSWVDQKL NSEGMEEARN CGKQLKALNF EFDLVFTSVL
     NRSIHTAWLI LEELGQEWVP VESSWRLNER HYGALIGLNR EQMALNHGEE QVRLWRRSYN
     VTPPPIEESH PYYQEIYNDR RYKVCDVPLD QLPRSESLKD VLERLLPYWN ERIAPEVLRG
     KTILISAHGN SSRALLKHLE GISDEDIINI TLPTGVPILL ELDENLRAVG PHQFLGDQEA
     IQAAIKKVED QGKVKQAKK
//
